Digital health startup Transcarent takes Accolade private in $621 million deal
1. Transcarent acquires Accolade for $621 million, enhancing offerings. 2. Accolade shares now valued at $7.03 each, no longer traded. 3. Acquisition completed amid resilience challenges in digital health sector. 4. Transcarent secured funding and previously earned accolades as a disruptor. 5. Accolade's public market exit reflects ongoing struggles in digital health.